Cartesian Therapeutics (RNAC) Change in Cash (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Change in Cash for 12 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 79.8% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$61.7 million (down 179.85% YoY), while the FY2025 annual figure was -$87.4 million, down 164.27% from the prior year.
• Change in Cash improved to -$6.5 million in Q1 2026 per RNAC's latest filing, from -$18.2 million in the prior quarter.
• Across five years, Change in Cash topped out at $132.0 million in Q3 2024 and bottomed at -$34.0 million in Q3 2023.
• Historically, Change in Cash has averaged $290588.2 across 5 years, with a median of -$6.6 million in 2024.
• On a YoY basis, Change in Cash climbed as much as 7098.83% in 2022 and fell as far as 989.29% in 2022.
• Cartesian Therapeutics' Change in Cash stood at -$6.4 million in 2022, then jumped by 57.97% to -$2.7 million in 2023, then plunged by 144.73% to -$6.6 million in 2024, then sank by 176.94% to -$18.2 million in 2025, then surged by 64.38% to -$6.5 million in 2026.
• Business Quant data shows RNAC's Change in Cash at -$6.5 million in Q1 2026, -$18.2 million in Q4 2025, and -$16.9 million in Q3 2025.